PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

NCT05035381 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

MSI-H Advanced Colorectal Cancer

Interventions

DRUG: Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen

Sponsor

Tianjin Medical University Cancer Institute and Hospital